These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25152496)

  • 1. HAS-BLED and CHA₂DS₂-VASc scores as predictors of bleeding and thrombotic risk after continuous-flow ventricular assist device implantation.
    Koene RJ; Win S; Naksuk N; Adatya SN; Rosenbaum AN; John R; Eckman PM
    J Card Fail; 2014 Nov; 20(11):800-7. PubMed ID: 25152496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of CHA2DS2-VASc and HAS-BLED Scores as Predictor of Thromboembolism and Bleeding After Left Ventricular Assist Device Implantation.
    Kemal HS; Ertugay S; Nalbantgil S; Ozturk P; Engin C; Yagdi T; Ozbaran M
    ASAIO J; 2017; 63(6):720-724. PubMed ID: 28187048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.
    Stulak JM; Deo S; Schirger J; Aaronson KD; Park SJ; Joyce LD; Daly RC; Pagani FD
    Ann Thorac Surg; 2013 Dec; 96(6):2161-7. PubMed ID: 24035302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
    Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weighing the risks: Thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease.
    Heidendael JF; Bokma JP; de Groot JR; Koolbergen DR; Mulder BJ; Bouma BJ
    Int J Cardiol; 2015; 186():315-20. PubMed ID: 25838183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
    Capodanno D; Rossini R; Musumeci G; Lettieri C; Senni M; Valsecchi O; Angiolillo DJ; Lip GY
    Int J Cardiol; 2015 Nov; 199():319-25. PubMed ID: 26241637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.
    Boyle AJ; Jorde UP; Sun B; Park SJ; Milano CA; Frazier OH; Sundareswaran KS; Farrar DJ; Russell SD;
    J Am Coll Cardiol; 2014 Mar; 63(9):880-8. PubMed ID: 24316083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device.
    Stulak JM; Lee D; Haft JW; Romano MA; Cowger JA; Park SJ; Aaronson KD; Pagani FD
    J Heart Lung Transplant; 2014 Jan; 33(1):60-4. PubMed ID: 24021944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation.
    Chao TF; Lin YJ; Tsao HM; Tsai CF; Lin WS; Chang SL; Lo LW; Hu YF; Tuan TC; Suenari K; Li CH; Hartono B; Chang HY; Ambrose K; Wu TJ; Chen SA
    J Am Coll Cardiol; 2011 Nov; 58(23):2380-5. PubMed ID: 22115643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pump replacement on outcome in advanced heart failure patients with left ventricular assist system.
    Iwashima Y; Yanase M; Horio T; Seguchi O; Murata Y; Fujita T; Toda K; Kawano Y; Nakatani T
    Artif Organs; 2013 Jul; 37(7):606-14. PubMed ID: 23692322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.